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Basal-like breast cancer (BLBC) is a form of breast 
cancer with generally poor prognosis that expresses basal 
cell markers and has an undifferentiated phenotype. 
The  majority  of  BLBC  is  also  classified  as  “triple-
negative breast cancer” due to the lack of expression of 
the estrogen and progesterone receptors and the lack of 
overexpression of HER2. BLBC is the only major breast 
cancer subtype with no targeted therapies, and although 
~20% of patients diagnosed with BLBC respond well to 
chemotherapy and are essentially cured, the remaining 
~80% succumb to their disease in just a few years after 
diagnosis. Therefore, new molecular-based approaches 
to treating BLBC are urgently needed. Several recent 
studies, including our report in the July 2011 issue of The 
Journal of Clinical Investigation [1], have used large-
scale, unbiased approaches to offer valuable insights into 
the details of complex aspects of BLBC.
In our report, we explored how intratumor 
heterogeneity impacts BLBC. After screening 1,576 
genes, we found that the JAK2/STAT3 pathway is 
preferentially required in CD44+CD24- breast cancer 
cells, which are most common in BLBC [2]. We identified 
a JAK2/STAT3 inhibitor, NVP-BSK805, that decreased 
basal-like breast tumor growth by eliminating this cell 
type, showing that targeting the JAK2/STAT3 pathway 
is a potential way to treat BLBC. Since we also found 
that basal-like breast tumors include CD24+ cells, which 
may also play a role in breast cancer progression [3], this 
would likely be most effective in combination with other 
cell type-specific drugs.
Other researchers have also looked into the 
importance of intratumor heterogeneity in BLBC by 
taking into account the added complexity of cell plasticity. 
Using a high-throughput screen for inhibitors of cells 
that had undergone an epithelial-mesenchymal transition 
(EMT), Gupta et al. [4] discovered that the compound 
salinomycin inhibited basal-like breast tumor growth. 
Thus, therapies that target particular cellular phenotypes 
could be useful in treating BLBC. Corroborating this 
work, LOXL2 was recently found to be involved in EMT 
and BLBC metastasis [5].
Important BLBC discoveries have also come from 
looking at tumors as a whole rather than at specific cancer 
cell populations. Sun et al. [6] screened all known human 
kinases and phosphatases for anchorage-independent 
growth suppression and thereby elucidated a complicated 
intracellular network in triple-negative breast cancer. 
They found that PTPN12 normally suppresses HER2 
and PDGFR-β and that inhibition of these together with 
lapatinib and sunitinib, respectively, greatly increased 
tumor growth inhibition. These results could be directly 
applicable to BLBC and suggest that drug combinations 
may often be necessary to kill the mixtures of cancer cells 
present in tumors.
In another study at the whole-tumor level, published 
in the same issue of The Journal of Clinical Investigation 
as our report, Lehmann et al. [7] classified 587 triple-
negative breast cancer cases into six subtypes using 
k-means clustering of gene expression data. Two of the 
identified subtypes were labeled as “basal-like” subtypes, 
and cell line models of them preferentially responded 
to cisplatin in culture and in mice. By scrutinizing 
intertumor heterogeneity, this work identified a potential 
treatment for BLBC, and it highlights the significance of 
personalizing breast cancer therapy.
In summary, recent advances in BLBC are helping 
to unravel its complexity by improving our understanding 
of intratumor and intertumor heterogeneity, cell plasticity, 
and intracellular networks. Successful targeted treatment 
strategies for BLBC will likely be designed based on the 
potential targets and tumor biology details presented here 
as well as additional findings from the studies discussed 
and research inspired by them. These will likely include 
tumor-specific  combinations  of  one  or  more  drugs  for 
multiple cell populations or states. Notably, such therapies 
may appear soon, as several of the inhibitors identified 
here, or related compounds, are already in clinical use or 
development.
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